Benitec Biopharma Limited Sponsored ADR

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

Benitec Biopharma to Present at the OPMD International Conference

First subject enrolled into the OPMD clinical development program First subject enrolled into the OPMD clinical development program

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program. The OPMD Natural History (NH) Study represents the 6-month pre-treatment observation period for each OPMD subject prior to the administration of BB-301 for the treatment of OPMD-related dysphagia. Upon the completion of 6-months of radiographic and clinical assessments required for the NH Study, participants will be eligible for enrollment into the BB-301 Phase 1b/2a treatment study in which BB-301 will be administered.

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S. Securities and Exchange Commission.

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66 per share of common stock and will expire on the fifth anniversary of such initial exercise date.

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66 per share of common stock and will expire on the fifth anniversary of such initial exercise date. The offering is expected to close on September 15, 2022, subject to customary closing conditions.

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year ended June 30, 2022. The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission.

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

Clovis Oncology

Invitae

Alaunos Therapeutics

Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022

HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year Q3 ended March 31, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2022, with the U.S. Securities and Exchange Commission.

Benitec Biopharma Releases Q3 2022 Financial Results

HAYWARD, Calif., Feb. 14, 2022 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the financial results for its Fiscal Year Q2 ended December 31, 2021.

Benitec Biopharma Discloses Q2 2022 Financial Results

HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the financial results for its Fiscal Year Q1 ended September 30, 2021.

Benitec Biopharma Discloses Q1 2022 Financial Results

HAYWARD, Calif., Sept. 20, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today provided an operational update and announced the financial results for its fiscal year ended June 30, 2021.

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

HAYWARD, Calif., Sept. 13, 2021 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an overview of the key elements of the BB-301 Phase 1b/2a clinical trial design.

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an update on the ongoing analyses of the large animal subjects treated with BB-301 in the Pilot Dosing Study.

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Regulatory Update Highlights: Regarding European Regulatory Interactions: The BB-301 Pilot Dosing Study was viewed as an appropriate dose range finding study The design of the ongoing GLP Biodistribution and Toxicology study was viewed as appropriate to support Phase 1b/2a testing of BB-301 The design of the Phase 1b/2a clinical trial can support the evaluation of BB-301 safety and clinical efficacy in key populations of OPMD patients Regarding U.S. Regulatory Interactions: Benitec has been granted a Type C meeting with the U.S. Food and Drug Administration ("FDA") in the fourth quarter of 2021 Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced significant progress regarding the regulatory interactions in Europe required to support advancement of the BB-301 development program towards the Phase 1b/2a clinical study in 2022.

Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,036,366 shares of common stock of the Company at a price to the public of $4.25 per share, less underwriting discounts and commissions.

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that it has entered into an underwriting agreement with H.C.

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) increased by 190.28% today. This is why it happened.

BNTC Stock Price Increased 190.28%: Why It Happened

Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gained 190.28% in Tuesday's session, closing at $9.26, and was giving back 11.12% to $8.23 in after-hours trading at last check.

Benitec BioPharma Shares Rally: Technical Levels To Watch

Dolphin Entertainment

Dolphin Entertainment Inc (NASDAQ: DLPN) shares are trading 150% higher after the company announced it launched a non-fungible token (NFT) creation and marketing division. Dolphin Entertainment produces and distributes digital entertainment content.

Why DLPN Stock And BNTC Stock Are Popping Off Today

Benitec Biopharma (BNTC) stock is rocketing higher in early morning trading on Tuesday after disclosing a new large stake in the company. The post BNTC Stock: One Big Investor Has Benitec Biopharma Shares Going Bonkers appeared first on InvestorPlace.

BNTC Stock: One Big Investor Has Benitec Biopharma Shares Going Bonkers

The shares of Benitec Biopharma Inc (NASDAQ: BNTC) are trading 92.5% higher at $6.14 in the early pre-market session on Tuesday.  What Happened: Benitec shares had closed at $3.19 on Monday.

Why Benitec Biopharma (BNTC) Stock Is Skyrocketing Today

The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) increased by over 80% pre-market. This is why it happened.

BNTC Stock Price Increased Over 80% Pre-Market: Why It Happened

Benitec Biopharma Inc (NASDAQ: BNTC) reports an interim analysis of the BB-301 Pilot Dosing study conducted in large animal subjects. BB-301 a genetic medicine directly injected into the pharyngeal muscles.

News for Benitec Biopharma Limited Sponsored ADR Stock (BNTC)